|
May 15
|
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
|
|
May 15
|
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
|
|
May 14
|
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
|
|
May 13
|
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 8
|
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
|
|
May 8
|
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
|
|
May 7
|
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
|
|
Apr 19
|
12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By
|
|
Apr 16
|
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
|
|
Apr 8
|
13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
|
|
Apr 4
|
Acumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s Treatment
|
|
Apr 4
|
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
|
|
Apr 3
|
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
|
|
Mar 28
|
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Mar 27
|
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript
|
|
Mar 27
|
Q4 2023 Acumen Pharmaceuticals Inc Earnings Call
|
|
Mar 26
|
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
|
|
Mar 21
|
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
|
|
Mar 21
|
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
|
|
Mar 19
|
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
|